U.S. drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s move for a lot less money.

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Simply meeting 5% growth estimates with no change in Pfizer's dirt-cheap valuation would produce over 12% annually -- boom, ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Pfizer announced last month that it was discontinuing development of its experimental weight-loss pill, danuglipron, after a trial participant experienced potential drug-induced liver injury.

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

But the deal gives Pfizer the option to also secure the drug’s commercialization rights in China. Furthermore, the big pharma has committed to a $100 million equity investment in 3SBio.

Pharmaceutical stocks, including Pfizer (NYSE: PFE), have recently been scrutinized after President Trump’s executive order instructing drug manufacturers to reduce medicine prices to align with ...